文献速递心律失常血脂与心血管预防

心房颤动患者口服抗凝结局的性别差异

Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2018-07-09

该研究基于香港临床数据库,纳入2010至2015年新诊断房颤并接受口服抗凝治疗的患者,按性别分别进行倾向评分匹配,比较直接口服抗凝药(DOAC)与华法林的有效性和安全性。匹配后男性4972例、女性4834例。结果显示,女性中DOAC较华法林与更低的颅内出血和全因死亡风险相关,而男性中未见此关联;两性中DOAC与华法林在缺血性卒中或系统性栓塞及胃肠道出血风险上相当。

要点

  • 女性房颤患者使用DOAC较华法林与更低的颅内出血和全因死亡风险相关。
  • 男性中DOAC与华法林在颅内出血和全因死亡风险上未见显著差异。
  • 两性中DOAC与华法林在缺血性卒中/系统性栓塞及胃肠道出血风险上相当。

核心结论

  • DOAC仅在女性中与更低的颅内出血和全因死亡风险相关,且女性中颅内出血风险降低在与抗凝控制良好的华法林使用者比较时仍存在。

研究设计与样本

  • 研究利用香港临床数据库识别2010至2015年新诊断房颤并处方口服抗凝药的患者,按性别分别进行倾向评分匹配,匹配后男性4972例、女性4834例。
  • 采用Cox回归在特定性别内比较缺血性卒中或系统性栓塞、颅内出血、胃肠道出血和全因死亡风险,并进一步按华法林抗凝控制质量分层分析。

主要发现

  • 女性中,DOAC较华法林与更低的颅内出血风险相关(HR 0.16;95%CI 0.06-0.40)和更低的严因死亡风险相关(HR 0.55;95%CI 0.39-0.77),男性中未见这些关联。
  • 治疗与性别的交互作用仅对颅内出血显著。
  • 女性中,与抗凝控制良好的华法林使用者相比,DOAC组颅内出血风险仍显著更低(HR 0.13;95%CI 0.02-1.00)。
  • 两性中DOAC与华法林在缺血性卒中或系统性栓塞及胃肠道出血风险上相当。

临床怎么用

  • 女性房颤患者选择口服抗凝药时,可考虑DOAC以降低颅内出血和全因死亡风险。
  • 男性房颤患者中DOAC与华法林的获益风险特征需个体化评估,本研究中两者在颅内出血和全因死亡上未见显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with atrial fibrillation are at a higher risk of stroke, despite treatment with warfarin. It is unclear if women treated with direct oral anticoagulants (DOACs) have better clinical outcomes, especially when considering the quality of anticoagulation control of warfarin. OBJECTIVES: This study compared the effectiveness and safety outcomes of DOACs versus warfarin in men and women with stratifications for anticoagulation control. METHODS: Patients newly diagnosed with atrial fibrillation and prescribed oral anticoagulants during 2010 to 2015 were identified using the Hong Kong clinical database. Propensity score matching was performed in men and women separately. Further analysis was conducted to stratify warfarin users according to their anticoagulation control. Cox regression was used to compare the risk of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastrointestinal bleeding, and all-cause mortality in the specific sex. RESULTS: There were 4,972 men and 4,834 women successfully matched in our cohort. Compared with warfarin, DOAC use was associated with a lower risk of ICH (hazard ratio [HR]: 0.16; 95% confidence interval [CI]: 0.06 to 0.40) and all-cause mortality (HR: 0.55; 95% CI: 0.39 to 0.77) in women but not in men. The treatment by sex interaction was significant for ICH only, and a significantly lower risk of ICH remained in the DOAC group when compared with warfarin users with good anticoagulation control (HR: 0.13; 95% CI: 0.02 to 1.00) among women only. The risks of ischemic stroke or systemic embolism and gastrointestinal bleeding with DOACs versus warfarin were comparable in both sexes. CONCLUSIONS: DOACs were associated with a lower risk of ICH and all-cause mortality in women only, where the association of lower ICH risk remained when compared with warfarin users with good anticoagulation control.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Law SWY, Lau WCY, Wong ICK, et al. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018. PMID: 30012320. doi:10.1016/j.jacc.2018.04.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。